- Home
- TALO vs HAE Comparison
TALO vs HAE Comparison
Compare TALO & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | HAE |
|---|---|---|
| Founded | 2011 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TALO | HAE |
|---|---|---|
| Price | $16.13 | $65.32 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $18.00 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 1.6M | 808.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | ★ $1,780,070,000.00 | $910,373,000.00 |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | ★ N/A | $25.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.67 | $47.32 |
| 52 Week High | $17.05 | $87.32 |
Technical Indicators
Market Signals| Indicator | TALO | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 67.49 |
| Support Level | $10.49 | $49.26 |
| Resistance Level | $16.28 | $66.86 |
| Average True Range (ATR) | 0.60 | 3.28 |
| MACD | 0.04 | 1.02 |
| Stochastic Oscillator | 64.81 | 96.53 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.